TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00195728
Drug: Hydrocodone/Acetaminophen on Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets twice daily
Study: NCT00931541
Drug: AZD6088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution. Each subject will receive a single-dose of AZD6088.
Study: NCT00931541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution. Each subject will receive a single-dose of placebo.
Study: NCT01394185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive placebo
Study: NCT02458729
Drug: 0.9% Normal Saline (intraoperative)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
Study: NCT02458729
Drug: 0.9% Normal Saline (3 hours after operation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline 20ml administered intravenously 3 hours after operation
Study: NCT02804763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion, 0,9% saline
Study: NCT04110145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
Study: NCT00953628
Drug: 250 mcg recombinant HCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus 250 mcg for ovulation triggering in IVF patients
Study: NCT04019002
Drug: Hyperpolarized 13C Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
Study: NCT00621283
Drug: RG1068 (Synthetic Human Secretin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study: NCT00775658
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
Study: NCT01871649
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
Study: NCT03907202
Drug: Daily injection of KBP/placebo for up to 28 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
Study: NCT02759510
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
Study: NCT04200963
Drug: IK-175
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
Study: NCT01300637
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical-appearing pill of placebo
Study: NCT00626236
Drug: SPN-810
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule taken three times a day
Study: NCT00626236
Drug: SPN-810
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule taken TID
Study: NCT00939185
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
Study: NCT00190957
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02845414
Drug: CD133KDEL (dCD133KDEL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
Study: NCT01302886
Drug: BHQ880
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568009
Drug: SLV320
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
Study: NCT02485184
Drug: Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy includes heparin and warfarin.
Study: NCT01655056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02299245
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: different dose of rosuvastatin treatment
Study: NCT01342055
Drug: Apetrol ES
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequences of administered drugs
Study: NCT00388609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
Study: NCT00321932
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
Study: NCT00734032
Drug: SB480848 80mg EC Tablet
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet once a day
Study: NCT00734032
Drug: SB480848 Placebo Tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet once a day
Study: NCT02295865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
Study: NCT00135304
Drug: Sensipar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet hydrochloride
Study: NCT02989857
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally
Study: NCT02989857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally
Study: NCT03247101
Drug: Urso group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodoxycholic acid, 200mg po tid x 6 months
Study: NCT03247101
Drug: Biotase group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
Study: NCT01944085
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup
Study: NCT01944085
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup
Study: NCT00497497
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00497497
Drug: PRO95780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00674102
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01168596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
Study: NCT00794430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, bid, for 13 weeks
Study: NCT00123630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given IV once every 2-4 weeks based on weight
Study: NCT01910155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03539614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
Study: NCT03386162
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
Study: NCT03699202
Drug: AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
Study: NCT03699202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
Study: NCT02150707
Drug: Dipeptidyl-Peptidase IV Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
Study: NCT00841815
Drug: Norvasc®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Tablet
Study: NCT00781261
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
Study: NCT00781261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the control group will receive a placebo drug for a similar period
Study: NCT00005980
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03578055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
Study: NCT00009178
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00809822
Drug: NPB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin
Study: NCT00809822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline
Study: NCT02071615
Drug: caffein 200mg tablet given once by mouth
Normalized name: caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-arm, single-drug dosage comparison study
Study: NCT02071615
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04626726
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/㎡ for D-3 and D-2
Study: NCT00928668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo device for comparison
Study: NCT05085834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules once daily
Study: NCT02314793
Drug: ASP2205
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02314793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01628952
Drug: Transversus Abdominis Plane
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIA coelioscopic
Study: NCT01628952
Drug: Curare
Normalized name: Curare alkaloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAP coelioscopic
Study: NCT01416337
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg single dose tablet on Day 1 of study
Study: NCT01416337
Drug: GSK1120212B
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single administration of a slow 1 minute IV push on Day 1.
Study: NCT01836757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01417767
Drug: CHG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
Study: NCT03198403
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
Study: NCT00199927
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
Study: NCT00199927
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy
Study: NCT02720757
Drug: Spiolto Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium bromide + Olodaterol
Study: NCT01230411
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg ibuprofen in 250 cc saline administered IV
Study: NCT01761149
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
Study: NCT02427932
Drug: Ampicillin and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
Study: NCT02427932
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescribed to non-pregnant participants
Study: NCT00420511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once a day
Study: NCT03616340
Drug: Shoulder injection
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra articular or subacromial shoulder injection
Study: NCT03616340
Drug: knee injection
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-articular knee injection
Study: NCT02499237
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
Study: NCT00157872
Drug: MK0966; rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00157872
Drug: Comparator: naproxen tablet 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02908100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
Study: NCT04446052
Drug: GM-CSF priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04446052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01085903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
Study: NCT02296099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
Study: NCT02971839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02085863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Study: NCT02429960
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
Study: NCT01212900
Drug: Statins, HMG CoA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy
Study: NCT00278161
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg/day on Days 15, 16, 17, and 18.
Study: NCT00865748
Drug: CLUCOPHAGE® XR 500 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study: NCT01418456
Drug: antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
Study: NCT00548886
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
Study: NCT00950521
Drug: convention therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiplatelet
Study: NCT00355043
Drug: Zinc sulphate 20 mg
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03379974
Drug: DDAVP Inhalant Product
Normalized name: DDAVP Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
Study: NCT01115504
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg daily for 30 days
Study: NCT04669795
Drug: Cissus Quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
Study: NCT02487186
Drug: Doxicicline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
Study: NCT00687076
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
Study: NCT00822094
Drug: Intensive Salvage Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02644551
Drug: CELEXT07
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00647647
Drug: Lamisil® Tablets 250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg, single dose fasting
Study: NCT02477748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet PO, taken once daily for 10 weeks.
Study: NCT00284128
Drug: AVE7688
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (capsules)
Study: NCT01021527
Drug: Comparator: Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration of exenatide 5ug by subcutaneous injection
Study: NCT01021527
Drug: Comparator: Treatment C
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration of exenatide 10ug by subcutaneous injection
Study: NCT02892370
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 tablets (10 mg)
Study: NCT00679614
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
Study: NCT03884673
Drug: DTG+ 3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
Study: NCT00633685
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
Study: NCT00633685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
Study: NCT01524406
Drug: HPP593
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, twice a day.
Study: NCT01524406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, twice a day.
Study: NCT01862003
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle